Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer

Trial Status: active

This phase II trial tests how well lenvatinib and pembrolizumab work in treating patients with anorectal squamous cell cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced), or that has spread from where it first started (primary site) to other places in the body (metastatic). Lenvatinib is an antiangiogenic agent. It works by stopping the formation of blood vessels that tumors need to grow. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenvatinib in combination with pembrolizumab may be an effective treatment option for patients with unresectable, locally advanced, or metastatic anorectal squamous cell cancer.